Phase 1 clinical trial demonstrated that MUC1 positive metastatic seminal vesicle cancer can be effectively eradicated by modified Anti-MUC1 chimeric antigen receptor transduced T cells

About this Attention Score

• In the top 25% of all research outputs scored by Altmetric
• High Attention Score compared to outputs of the same age (91st percentile)
• High Attention Score compared to outputs of the same age and source (99th percentile)